DBV Technologies S.A.
DBV.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$252.37M
Close$
Share Statistics
| Market cap | $252.37 Million |
|---|---|
| Enterprise Value | $85.17 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -102.70% |
|---|---|
| Return on Assets | -73.81% |
| Return on Invested Capital | -50.62% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About DBV Technologies
170 employees
CEO: Daniel Tasse DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase II...